Infectious Diseases Molecular Diagnostics Market - Growth, Share, Opportunities & Competitive Analysis, 2024 – 2032
Description
Market Overview
The Infectious Diseases Molecular Diagnostics Market is projected to grow from USD 21.53 billion in 2024 to USD 37.54 billion by 2032, with a compound annual growth rate (CAGR) of 7.2% from 2024 to 2032.
The market is primarily driven by the increasing global burden of infectious diseases, including viral infections, bacterial outbreaks, and emerging pathogens. Molecular diagnostics provide significant advantages over traditional methods, offering faster results, enhanced sensitivity, and the ability to detect infections at earlier stages. Furthermore, the growing awareness of personalized medicine and the rising demand for point-of-care diagnostics are accelerating the adoption of molecular diagnostic solutions. Governments and healthcare organizations are heavily investing in molecular diagnostics as part of their public health strategies, particularly in response to pandemics and global health emergencies like COVID-19. Additionally, advancements in technologies such as real-time PCR and next-generation sequencing (NGS) are improving diagnostic accuracy, fueling the market’s growth.
Market Drivers
Technological Advancements in Molecular Diagnostics
Technological progress in molecular diagnostics is a key driver of market expansion. The development of advanced techniques, such as next-generation sequencing (NGS), real-time polymerase chain reaction (PCR), and CRISPR-based diagnostics, has enhanced the accuracy and speed of infectious disease detection. These technologies enable pathogen detection at the genetic level, offering superior sensitivity compared to traditional diagnostic methods. Additionally, improvements in automation and the integration of molecular diagnostics with point-of-care devices have enabled faster, on-site results, making them ideal for clinical settings, emergency departments, and remote healthcare environments. As these technologies become more affordable and refined, their adoption is expected to rise, further driving market growth.
Market Challenges Analysis
High Costs of Diagnostic Equipment and Testing
A significant challenge in the Infectious Diseases Molecular Diagnostics market is the high cost of diagnostic equipment and tests. Advanced technologies such as PCR and next-generation sequencing (NGS) require sophisticated equipment and reagents, which can be costly for healthcare providers, especially in low-resource settings. For example, the Xpert MTB/RIF assay costs around $14.93 per test, and the MTBDR plus line probe assay costs approximately $23.46 per test. The high initial investment required for such diagnostic tools can be prohibitive for smaller healthcare facilities, limiting their widespread adoption. Moreover, the recurring costs for reagents, consumables, and equipment maintenance add to the financial burden, making it difficult for healthcare systems in developing regions to implement molecular diagnostic testing on a large scale.
Segmentation
By Technology:
Polymerase Chain Reaction (PCR)
In Situ Hybridization
Isothermal Nucleic Acid Amplification Technology (INAAT)
Chips and Microarrays
Mass Spectrometry
Sequencing
Others
By Product Type:
Instruments
Reagents
Services
By End Use:
Hospitals
Clinics
Diagnostic Laboratories
Research Institutes
By Application:
Respiratory Diseases
Tuberculosis
Meningitis
Gastrointestinal Tract Infections
HPV
Sexually Transmitted Infections
Sepsis
Drug Resistance Diseases
Other Infectious Diseases
By Region:
North America
U.S.
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Rest of Europe
Asia Pacific
China
Japan
India
South Korea
Southeast Asia
Rest of Asia Pacific
Latin America
Brazil
Argentina
Rest of Latin America
Middle East & Africa
GCC Countries
South Africa
Rest of the Middle East and Africa
Key Player Analysis
Abbott
Agilent Technologies, Inc.
Becton, Dickinson and Company
bioMérieux SA
Bio-Rad Laboratories, Inc.
Danaher Corporation
Hoffmann-La Roche Ltd
Grifols S.A.
Hologic, Inc. (Gen-Probe)
Illumina, Inc.
Qiagen
Siemens Healthineers AG
Sysmex Corporation
The Infectious Diseases Molecular Diagnostics Market is projected to grow from USD 21.53 billion in 2024 to USD 37.54 billion by 2032, with a compound annual growth rate (CAGR) of 7.2% from 2024 to 2032.
The market is primarily driven by the increasing global burden of infectious diseases, including viral infections, bacterial outbreaks, and emerging pathogens. Molecular diagnostics provide significant advantages over traditional methods, offering faster results, enhanced sensitivity, and the ability to detect infections at earlier stages. Furthermore, the growing awareness of personalized medicine and the rising demand for point-of-care diagnostics are accelerating the adoption of molecular diagnostic solutions. Governments and healthcare organizations are heavily investing in molecular diagnostics as part of their public health strategies, particularly in response to pandemics and global health emergencies like COVID-19. Additionally, advancements in technologies such as real-time PCR and next-generation sequencing (NGS) are improving diagnostic accuracy, fueling the market’s growth.
Market Drivers
Technological Advancements in Molecular Diagnostics
Technological progress in molecular diagnostics is a key driver of market expansion. The development of advanced techniques, such as next-generation sequencing (NGS), real-time polymerase chain reaction (PCR), and CRISPR-based diagnostics, has enhanced the accuracy and speed of infectious disease detection. These technologies enable pathogen detection at the genetic level, offering superior sensitivity compared to traditional diagnostic methods. Additionally, improvements in automation and the integration of molecular diagnostics with point-of-care devices have enabled faster, on-site results, making them ideal for clinical settings, emergency departments, and remote healthcare environments. As these technologies become more affordable and refined, their adoption is expected to rise, further driving market growth.
Market Challenges Analysis
High Costs of Diagnostic Equipment and Testing
A significant challenge in the Infectious Diseases Molecular Diagnostics market is the high cost of diagnostic equipment and tests. Advanced technologies such as PCR and next-generation sequencing (NGS) require sophisticated equipment and reagents, which can be costly for healthcare providers, especially in low-resource settings. For example, the Xpert MTB/RIF assay costs around $14.93 per test, and the MTBDR plus line probe assay costs approximately $23.46 per test. The high initial investment required for such diagnostic tools can be prohibitive for smaller healthcare facilities, limiting their widespread adoption. Moreover, the recurring costs for reagents, consumables, and equipment maintenance add to the financial burden, making it difficult for healthcare systems in developing regions to implement molecular diagnostic testing on a large scale.
Segmentation
By Technology:
Polymerase Chain Reaction (PCR)
In Situ Hybridization
Isothermal Nucleic Acid Amplification Technology (INAAT)
Chips and Microarrays
Mass Spectrometry
Sequencing
Others
By Product Type:
Instruments
Reagents
Services
By End Use:
Hospitals
Clinics
Diagnostic Laboratories
Research Institutes
By Application:
Respiratory Diseases
Tuberculosis
Meningitis
Gastrointestinal Tract Infections
HPV
Sexually Transmitted Infections
Sepsis
Drug Resistance Diseases
Other Infectious Diseases
By Region:
North America
U.S.
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Rest of Europe
Asia Pacific
China
Japan
India
South Korea
Southeast Asia
Rest of Asia Pacific
Latin America
Brazil
Argentina
Rest of Latin America
Middle East & Africa
GCC Countries
South Africa
Rest of the Middle East and Africa
Key Player Analysis
Abbott
Agilent Technologies, Inc.
Becton, Dickinson and Company
bioMérieux SA
Bio-Rad Laboratories, Inc.
Danaher Corporation
Hoffmann-La Roche Ltd
Grifols S.A.
Hologic, Inc. (Gen-Probe)
Illumina, Inc.
Qiagen
Siemens Healthineers AG
Sysmex Corporation
Table of Contents
220 Pages
- CHAPTER NO. 1 : INTRODUCTION
- 1.1.1. Report Description
- Purpose of the Report
- USP & Key Offerings
- 1.1.2. Key Benefits for Stakeholders
- 1.1.3. Target Audience
- 1.1.4. Report Scope
- CHAPTER NO. 2 : EXECUTIVE SUMMARY
- 2.1. [Infectious Diseases Molecular Diagnostics Market] Snapshot
- 2.1.1. [Infectious Diseases Molecular Diagnostics Market], 2018 - 2032 (USD Million)
- CHAPTER NO. 3 : [Infectious Diseases Molecular Diagnostics Market] – INDUSTRY ANALYSIS
- 3.1. Introduction
- 3.2. Market Drivers
- 3.3. Market Restraints
- 3.4. Market Opportunities
- 3.5. Porter’s Five Forces Analysis
- CHAPTER NO. 4 : ANALYSIS COMPETITIVE LANDSCAPE
- 4.1. Company Market Share Analysis – 2023
- 4.2. [Infectious Diseases Molecular Diagnostics Market] Company Revenue Market Share, 2023
- 4.3. Company Assessment Metrics, 2023
- 4.4. Start-ups /SMEs Assessment Metrics, 2023
- 4.5. Strategic Developments
- 4.6. Key Players Product Matrix
- CHAPTER NO. 5 : PESTEL & ADJACENT MARKET ANALYSIS
- CHAPTER NO. 6 : [Infectious Diseases Molecular Diagnostics Market] – BY [Based on Product Type] ANALYSIS
- CHAPTER NO. 7 : [Infectious Diseases Molecular Diagnostics Market] – BY [By Application] ANALYSIS
- CHAPTER NO. 8 : [Infectious Diseases Molecular Diagnostics Market] – BY [By End Use] ANALYSIS
- CHAPTER NO. 9 : [Infectious Diseases Molecular Diagnostics Market] – BY [By Technology] ANALYSIS
- CHAPTER NO. 10 : [Infectious Diseases Molecular Diagnostics Market] – BY [By Region] ANALYSIS
- CHAPTER NO. 11 : COMPANY PROFILES
- 11.1. Abbott
- 11.1.1. Company Overview
- 11.1.2. Product Portfolio
- 11.1.3. SWOT Analysis
- 11.1.4. Business Strategy
- 11.1.5. Financial Overview
- 11.2. Agilent Technologies, Inc.
- 11.3. Becton, Dickinson and Company
- 11.4. bioMérieux SA
- 11.5. Bio-Rad Laboratories, Inc.
- 11.6. Danaher Corporation
- 11.7. Hoffmann-La Roche Ltd
- 11.8. Grifols S.A.
- 11.9. Hologic, Inc. (Gen-Probe)
- 11.10. Illumina, Inc.
- 11.11. Qiagen
- 11.12. Siemens Healthineers AG
- 11.13. Sysmex Corporation
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
